Predictive value of positron emission tomography/computed tomography to assess early treatment response to dual human epidermal growth factor receptor 2 (HER2) blockade without chemotherapy for HER2-positive metastatic breast cancer: Are we ready to embrace this "early metabolic look" strategy? Journal Article

  

Authors:	Jhaveri, K.; Ulaner, G. A.; Dickler, M. N.
Article Title:	Predictive value of positron emission tomography/computed tomography to assess early treatment response to dual human epidermal growth factor receptor 2 (HER2) blockade without chemotherapy for HER2-positive metastatic breast cancer: Are we ready to embrace this "early metabolic look" strategy?
Keywords:	treatment response; overall survival; disease course; cancer recurrence; cancer combination chemotherapy; drug efficacy; outcome assessment; metabolism; progression free survival; editorial; fluorodeoxyglucose f 18; computer assisted emission tomography; trastuzumab; breast metastasis; lapatinib; predictive value; pertuzumab; trastuzumab emtansine; human; priority journal
Journal Title:	Journal of Clinical Oncology
Volume:	33
Issue:	24
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2015-08-20
Start Page:	2591
End Page:	2593
Language:	English
DOI:	10.1200/jco.2015.62.3082
PROVIDER:	scopus
PUBMED:	26195716
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84940472651&partnerID=40&md5=7db9665325a288a55e85eb323500440f
Notes:	Export Date: 2 October 2015 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/81273